At the conference, AstraZeneca and Daiichi Sankyo will present their case for Dato-DXd in NSCLC, while BioNTech and Merus ...

Dysregulated cell signaling underlies various diseases, emphasizing the importance of understanding these pathways for ...

2024 — Researchers have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the STK11 ... Scientists Discover That Special ...

Kelun-Biotech has become the second drugmaker to bring a TROP2-directed antibody-drug conjugate to regulatory approval, ...

Akeso, Inc. (9926. HK) ('Akeso' or the 'Company') is pleased to announce that two of its independently developed, globally ...

Stanford University medical professor Dr. Bryant Lin was diagnosed with stage IV lung cancer despite never smoking. Now, he's ...

Bevacizumab biosimilars have the potential to expand access and reduce costs without compromising patient outcomes in ...

Sac-TMT, also known as SKB264 or MK-2870, represents the first asset in Kelun’s multitarget, multibillion-dollar ADC ...

2024 年 12 月 6 日 - 8 日，欧洲肿瘤内科学会亚洲年会（ESMO Asia）将在新加坡盛大召开。本届会议将汇聚全球专家学者，集中展示和讨论肿瘤学领域的最新科学和临床进展，为肿瘤领域带来一场学术盛宴。此次会议中，「Dato-DXd ...

前言随着精准医学的不断发展，表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）推动了晚期非小细胞肺癌（NSCLC）的治疗变革，其在围术期领域的探索成为目前发展的重要方向之一。目前，EGFR-TKI为早期EGFR突变NSCLC的术后辅助靶向治疗带来了 ...

AI-Enabled Drug Discovery is on the verge of a new revolution, with the first data emerging from exciting research indicating ...

With targeted treatment and a strong support group, she now lives a full life and serves the community that had her back.